Medical device and software developer BrainTale has raised more than one million euros in its first financing round.
Founded in 2018, Paris-based BrainTale has received the CE Mark for brainQuant, a software-as-a-service (SaaS) offering for quantifying brain lesions on diffusion MRI exams. The firm is also developing BrainScore-coma, a SaaS application that combines brainQuant with artificial intelligence (AI) algorithms to predict coma emergence in intensive care patients after severe brain injuries. BrainTale said it expects to receive the CE Mark for BrainScore-coma by mid-2021.
The funding package includes a loan from Bpifrance, as well as investments from business angels, as well as industry and healthcare professionals, according to BrainTale. The company said it will use the funds to implement its development and commercialization strategy.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
